Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Radiance RDX System Expanded Clinical Trials Targeted For Year-End

This article was originally published in The Gray Sheet

Executive Summary

Radiance Medical hopes to receive final FDA approval for its RDX balloon catheter radiation delivery system in the second half of 2001.

You may also be interested in...



SVG Potential Indication Could Bring A Glow To Brachytherapy Contender

The solid beta radiation source balloon technology employed by Radiance Medical Systems' RDX radiation delivery catheter will present an advantage over competing intravascular brachytherapy systems in treating restenotic saphenous vein grafts (SVG), according to the Irvine, California firm.

SVG Potential Indication Could Bring A Glow To Brachytherapy Contender

The solid beta radiation source balloon technology employed by Radiance Medical Systems' RDX radiation delivery catheter will present an advantage over competing intravascular brachytherapy systems in treating restenotic saphenous vein grafts (SVG), according to the Irvine, California firm.

Medtronic Acquires XRT, Gains Brachytherapy Restenosis Technology

Medtronic plans to submit an investigational device exemption application in the third quarter for the soft x-ray brachytherapy technology it has obtained as a result of the recent acquisition of privately held XRT Corp.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel